ERRATUM

Erratum to: Intact IFN- γ R1 Expression and Function Distinguishes Langerhans Cell Histiocytosis From Mendelian Susceptibility to Mycobacterial Disease

Willemijn T. Quispel¹ • Janine A. Stegehuis-Kamp¹ • Susy J. Santos¹ •
Annelies van Wengen² • Edward Dompeling³ • R. Maarten Egeler^{4,5} •
Esther van de Vosse² • Astrid G. S. van Halteren¹

Published online: 19 January 2016
© Springer Science+Business Media New York 2016

Erratum to: J Clin Immunol (2014)
DOI 10.1007/s10875-013-9959-1

The original version of this article unfortunately contained mistakes in Table 1. The correct version is presented below.

The online version of the original article can be found at <http://dx.doi.org/10.1007/s10875-013-9959-1>.

✉ Astrid G. S. van Halteren
a.g.s.van_Halteren@lumc.nl

- ¹ Immunology Laboratory, Willem Alexander Children's Hospital, Leiden University Medical Center, Leiden, The Netherlands
- ² Department of Infectious diseases, Leiden University Medical Center, Leiden, The Netherlands
- ³ Department of Paediatric Pulmonology, Maastricht University Medical Center, Maastricht, The Netherlands
- ⁴ Willem Alexander Children's Hospital, Leiden University Medical Center, Leiden, The Netherlands
- ⁵ Division of Hematology/Oncology, Hospital for Sick Children/University of Toronto, Toronto, Canada

Table 1 Published patients with LCH-mimicking features that eventually turned out to have MSMD (1–5) and our case (6)

Case	Gender	Country	BCG vaccination (age)	Clinical course (age)	Therapy (age)	IFN- γ R1 mutation	Family history
1 [2]	Female	N.A.	Yes, slow healing scar (1 month)	Therapy-non responding poly-osteolytic lesions (2)	Vinblastine, prednisolone, 6-mercaptopurin (2); antimycobacterial agents and IFN- γ supplementation (2)	Heterozygous TTAA deletion (exon 6)	Mother also developed osteolytic lesions
2 [2]	Female	N.A.	Yes, slow healing scar (1 month)	Progressive osteolytic lesions and lung involvement (2); osteolytic lesions, fever, night sweats (10)	Radiotherapy, vinblastine, steroids (2); rifampicin, isoniazid (10); anti-tuberculous agents, IFN- γ supplementation (10)	Heterozygous TTAA deletion (exon 6)	
3 [3]	Male	Spain	N.A.	Juvenile chronic arthritis (2); lumbar pain (3); osteomyelitis (6–7); multicystic dysfunction syndrome, septic shock, exitus (7); death (7)	Anti-mycobacterial therapy: ethambutol, rifabutin, ciprofloxacin and clarithromycin (6)	Homozygous V63G (exon 2)	Non-consanguineous parents
4 [3,5]	Female	Poland	Yes, no complications (1 month)	Fever, diffuse bone pain and general fatigue, osteolytic lesion left iliac bone (20), multifocal osteomyelitis with brain and lung infiltration (21); spondylodisitis and progressive brain lesions (22)	Steroids, etoposide and cyclosporine A (20); rifampicin, isoniazid, streptomycin, corticosteroids (20,8); amikacin, rifabutin, cycloserine and clofazimine (21); rifabutin, clarithromycin, clofazimine and cotrimoxazole and IFN- γ supplementation (22)	Homozygous I87T (exon 3)	Non-consanguineous parents
5 [4]	Male	Belgium	N.A.	Eczematoid and maculopapular skin lesions, disseminated lymphadenopathies, hepatosplenomegaly (2); recurrence of maculopapular rash and lymphadenopathy (2,5)	Clarithromycin, cotrimoxazole (2); BMT (HLA-identical sister), cyclosporin A, methylprednisolone 2.5)	Homozygous C77F (exon 3)	Consanguineous parents; healthy sister
6	Male	the Netherlands	No	Recurrent fever, pneumonia (4); headaches, lymphadenopathies, lesions in spleen and poly-osteolytic lesions (5)	Penicillin; diclofenac, rifampicin, clarithromycin	TTAA deletion (exon 6)	Non-consanguineous parents

N.A. not available